Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.

Tripathi R, Liu Z, Jain A, Lyon A, Meeks C, Richards D, Liu J, He D, Wang C, Nespi M, Rymar A, Wang P, Wilson M, Plattner R
Nat Commun. 2020 Oct 29;11(1):5463. doi: 10.1038/s41467-020-19075-3. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.